Research Partnership Launches Alzheimer's Tracker

Healthcare specialist Research Partnership has launched a new Alzheimer's Disease tracker in Germany, Japan and the US, as part of of its syndicated Therapy Watch series. The firm plans to expand the service to other key European markets this year.

Alzheimer's Disease is the most prevalent form of dementia and a leading cause of mortality worldwide: around 32m people were diagnosed with the disease in G7 countries alone last year, with life expectancy typically seven to ten years for those diagnosed with Alzheimer's Disease at age 60 to 70. More than seventy assets are currently in Phase II or later clinical trials for treatment.

The new study will collect patient record form (PRF) insights via online interviews with a panel of Neurologists, GPs, Geriatricians and Psychiatrists who specialize in early-stage Alzheimer's patients, promising an understanding of the complete patient journey and of collaborative efforts to combat the disease by multidisciplinary teams.

Research Partnership says the patient records used are exceptionally thorough, encompassing vital information such as demographics, diagnostic tests including innovative imaging and biomarker tests, detailed symptoms and associated conditions of Alzheimer's Disease, current treatments, and uptake of new treatment launches.

A year ago the company appointed Gareth Phillips (pictured) as its new CEO, reporting to Colin Stanley, President of its parent firm Inizio Advisory.

Web site: www.researchpartnership.com .

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.